Peapod Lane Capital LLC Purchases New Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Peapod Lane Capital LLC acquired a new position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 328,581 shares of the company’s stock, valued at approximately $1,101,000. Peapod Lane Capital LLC owned about 0.39% of Atea Pharmaceuticals at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Intech Investment Management LLC bought a new stake in shares of Atea Pharmaceuticals during the 3rd quarter worth $36,000. Dynamic Technology Lab Private Ltd purchased a new stake in Atea Pharmaceuticals during the third quarter worth about $37,000. China Universal Asset Management Co. Ltd. raised its position in Atea Pharmaceuticals by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 16,237 shares of the company’s stock worth $54,000 after acquiring an additional 6,343 shares during the period. Zacks Investment Management purchased a new position in Atea Pharmaceuticals in the third quarter valued at about $80,000. Finally, Virtu Financial LLC bought a new position in shares of Atea Pharmaceuticals during the 3rd quarter valued at approximately $99,000. Institutional investors own 86.67% of the company’s stock.

Insider Buying and Selling at Atea Pharmaceuticals

In other news, Director Franklin M. Berger sold 359,606 shares of the company’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $2.85, for a total transaction of $1,024,877.10. Following the transaction, the director now owns 451,897 shares of the company’s stock, valued at $1,287,906.45. This represents a 44.31 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 17.80% of the stock is owned by corporate insiders.

Atea Pharmaceuticals Stock Performance

Shares of AVIR stock opened at $3.11 on Thursday. The company has a 50 day moving average of $3.17 and a 200-day moving average of $3.40. Atea Pharmaceuticals, Inc. has a 12-month low of $2.75 and a 12-month high of $4.60.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.